The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Turning Point and Repare are left nursing heavy losses, while Relay just about weathers a storm.
And four other potential targets that could make sense for the beleaguered group.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
The first look at Turning Point’s TPX-0022 shows signs of activity beyond cMet inhibitors’ proven use in lung cancer.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.